Q1 2024 Nykode Therapeutics ASA Earnings Call Transcript
Greetings, and welcome to the Nykode Therapeutics Q1 2024 financial results presentation. (Operator Instructions) As a reminder, this conference is being recorded.
Is now my pleasure to introduce Chief Executive Officer, Michael Engsig. Thank you. You may begin.
Thank you very much, Darryl and all the participants. A very warm welcome to this Q1 report that we assume you're all familiar with our forward-looking statement. And on that note we'll move forward, I am very pleased to have with me here today are Agnete Fredriksen, our Chief Scientific Officer, Head of Business Development and Co-Founder; Harald Gurvin, our Chief Financial Officer; and Klaus Edvardsen, our Chief Research and Development Officer. And together, we will take you through the highlights of the quarter as well as the financial results.
A quick look as an introduction from my side. First quarter was yet another exciting quarter with very solid progress for Nykode. We presented the very important top line
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
